MarketPulse

ALS

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Tiziana Life Sciences

Tiziana's Long COVID Treatment Shows Promise in Peer-Reviewed Study

Tiziana Life Sciences reports positive preclinical data for intranasal foralumab in treating Long COVID neuroinflammation and cognitive dysfunction.
TLSAALSAlzheimer's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Medicinova, Inc.

MediciNova to Present Pipeline Progress at 2026 ROTH Conference

MediciNova executives to present clinical pipeline at March 2026 ROTH Conference, conducting direct investor meetings in Dana Point.
MNOVclinical trialsbiopharmaceutical
BenzingaBenzinga··Prnewswire

Brainstorm Cell Therapeutics Completes $2M February Fundraising Round

Brainstorm Cell Therapeutics raised $2M in February through private placement at $0.60/share. Funds support general operations, regulatory work, and Phase 3b trial preparations for ALS therapy NurOwn.
BCLIprivate placementcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

CervoMed's neflamapimod gains inclusion in UK's accelerated ALS clinical trial platform

CervoMed's neflamapimod selected for UK's accelerated EXPERTS-ALS trial platform. The drug will be evaluated in 35-80 ALS patients over 18-24 weeks.
CRVOclinical trialALS